Humacyte, Inc. logo HUMA - Humacyte, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 10
HOLD 1
SELL 0
STRONG
SELL
0
| PRICE TARGET: $3.00 DETAILS
HIGH: $3.00
LOW: $3.00
MEDIAN: $3.00
CONSENSUS: $3.00
UPSIDE: 185.71%

About Humacyte, Inc. (https://www.humacyte.com)

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Key Executives

NAME TITLE DOB SALARY
Laura E. Niklason Founder, President, Chief Executive Officer & Director 1963 $902,183 USD
Dale A. Sander Chief Financial Officer, Chief Corporate Development Officer & Treasurer 1960 $735,503 USD
Shamik J. Parikh Chief Medical Officer 1973 $700,401 USD
Heather Connelly Executive Vice President Regulatory Affairs & Quality
Jim Mercadante Chief Commercial Officer
Lisa Molyneux Executive Vice President of Enterprise Planning & Analysis
Rick McElheny Senior Vice President of Business Development
Sabrina Osborne Chief People Officer
Todd E. Rasmussen Chief Surgical Officer

Company Peers

Peer analysis pending, check back in 1-2 minutes.